2. Karolinska Institute (KI)


KI, founded in 1810, is the Sweden’s only university especially focusing on biomedical sciences. In addition, KI annually awards the Nobel Prize in Physiological or Medicine. KI ranks as one of the world’s leading medical universities, related to the quality of its research activities, which today account for 40 percent of all medical research in Sweden.

The Department of Oncology-Pathology focuses on basic, translational and clinical research and education related to cancer; hence forming an ideal environment to carry out intended research in DeepMatch project. Approximately 300 people from over 40 nations are currently working at the department. KI has 37 research groups working on cutting edge cancer research with strong translational focus.

It is also a founding university of Science for Life Laboratory, which is a national institution for the advancement of molecular biosciences in Sweden. It is founded as a national research infrastructure by the access for the cutting-edge instrumentation and deep scientific expertise necessary to be internationally competitive and health related research at the highest international level providing cutting edge knowledge on genomics, proteomics, imaging and functional assays for DART project.

Role in CCE_DART

KI cancer proteogenomic research group have seminal contribution on integrating genomics and proteomics data to gain knowledge and apply genotype-phenotype connection to improve cancer therapy. Here the knowledge on developing new molecular markers and integrate multi-layer information towards systems predictive oncology will contribute significantly to reach the CCE_DART goals. Further, proteogenomic group have developed the Molecular tumor Board Portal, a clinical support system employed -among others, by the Cancer core Europe to interpret the patient’s genetic and tumor genomic data. The portal automates data capture, interpretation and reporting in the context of the Basket of Baskets trial.

In addition, key members of the clinical trial design and implementation of Karolinska University Hospital will be involved in the CCE_DART project, supporting the development of the clinical tasks as well as the technological tasks in the translational setting.